Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.

Sigrun Lange; Sharad Kholia; Uchini S Kosgodage; Jameel Inal

doi:10.1007/978-3-319-58244-3

Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.

Sigrun Lange, Sharad Kholia, Uchini S Kosgodage, Jameel Inal

Research output: Chapter in Book/Report/Conference proceeding › Chapter

1 Citation (Scopus)

Abstract

Cellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.

Original language	English
Title of host publication	Protein Deimination in Human Health and Disease
Editors	Anthony Nicholas, Sanjoy Bhattacharya, Paul Thompson
Publisher	Springer Nature Link
Pages	413-425
Number of pages	12
Edition	2
ISBN (Electronic)	978-3-319-58244-3
ISBN (Print)	978-3-319-58243-6
DOIs	https://doi.org/10.1007/978-3-319-58244-3
Publication status	Published - 2017

Access to Document

10.1007/978-3-319-58244-3

Cite this

@inbook{f5b3191ac8f34c368d7bbc10a49d5c41,

title = "Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.",

abstract = "Cellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.",

author = "Sigrun Lange and Sharad Kholia and Kosgodage, {Uchini S} and Jameel Inal",

note = "Lange, Sigrun, et al, 'Treatment of prostrate cancer using deimination antagonists and microvesicle technology', in Anthony Nicholas, Sanjoy Bhattacharya, and Paul Thompson, eds., Protein Deimination in Human Health and Disease, 2nd. Edition, (Switzerland: Springer, 2017), ISBN: 978-3-319-58243-6, eBOOK ISBN: 978-3-319-58244-3, doi: 10.1007/978-3-319-58244-3.",

year = "2017",

doi = "10.1007/978-3-319-58244-3",

language = "English",

isbn = "978-3-319-58243-6",

pages = "413--425",

editor = "Anthony Nicholas and Sanjoy Bhattacharya and Paul Thompson",

booktitle = "Protein Deimination in Human Health and Disease",

publisher = "Springer Nature Link",

address = "Netherlands",

edition = "2",

}

Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology. / Lange, Sigrun; Kholia, Sharad; Kosgodage, Uchini S et al.
Protein Deimination in Human Health and Disease. ed. / Anthony Nicholas; Sanjoy Bhattacharya; Paul Thompson. 2. ed. Springer Nature Link, 2017. p. 413-425.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.

AU - Lange, Sigrun

AU - Kholia, Sharad

AU - Kosgodage, Uchini S

AU - Inal, Jameel

N1 - Lange, Sigrun, et al, 'Treatment of prostrate cancer using deimination antagonists and microvesicle technology', in Anthony Nicholas, Sanjoy Bhattacharya, and Paul Thompson, eds., Protein Deimination in Human Health and Disease, 2nd. Edition, (Switzerland: Springer, 2017), ISBN: 978-3-319-58243-6, eBOOK ISBN: 978-3-319-58244-3, doi: 10.1007/978-3-319-58244-3.

PY - 2017

Y1 - 2017

N2 - Cellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.

AB - Cellular microvesicle (MV) release, which occurs in most eukaryotic cells, is also involved in cancer progression and has recently been associated with peptidylarginine deiminase (PAD)-driven protein deimination. Evidence points to the involvement of deiminated cytoskeletal proteins and changes in histone deimination in the mechanism of MV biogenesis. Elevated PAD expression observed in cancers may contribute to increased MV shedding from cancer cells and contribute to cancer progression. The use of pan-PAD inhibitor Cl-Amidine (Cl-Am) showed that, following the pharmacological inhibition of PAD-mediated deimination, cellular MV release was significantly reduced, rendering prostate cancer cells significantly more susceptible to chemotherapeutic drugs. Combined Cl-Am and methotrexate (MTX) treatment of prostate cancer cells increased the cytotoxic effect of MTX. Refined PAD inhibitors that selectively manipulate MV biogenesis may form part of novel combination therapies in cancer treatment.

U2 - 10.1007/978-3-319-58244-3

DO - 10.1007/978-3-319-58244-3

M3 - Chapter

SN - 978-3-319-58243-6

SP - 413

EP - 425

BT - Protein Deimination in Human Health and Disease

A2 - Nicholas, Anthony

A2 - Bhattacharya, Sanjoy

A2 - Thompson, Paul

PB - Springer Nature Link

ER -

Treatment of Prostate Cancer Using Deimination Antagonists and Microvesicle Technology.

Abstract

Access to Document

Fingerprint

Cite this